Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kymera rapeutics

Why Kymera Therapeutics Stock Is Gaining Wednesday

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell Lymphoma (PTCL).

Analyst Ratings for Kymera Therapeutics

Analyst Ratings for Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying

Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying

Although the Dow Jones dropped more than 200 points on Tuesday, there were a few notable insider trades.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Kymera Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million, resulting in a 8.21% decrease from last quarter.

Executives Buy Around $141M Of 4 Stocks

Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Kymera Therapeutics: Q1 Earnings Insights

Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings for Kymera Therapeutics

Analyst Ratings for Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET

Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET

Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this link to access the live webcast.

1

People

Dara Khosrowshahi

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Uber Technologies

Archer Aviation

Fifth Third Bancorp

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play